BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

33 related articles for article (PubMed ID: 3611859)

  • 1. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
    Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
    An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late relapses in leprosy patients in Brazil: 10-year post-trial of uniform multidrug therapy (U-MDT/CT-BR).
    Penna GO; Pontes MAA; Talhari S; Gonçalves HS; Talhari C; Pessoa AS; Pedroza V; Bührer-Sékula S; Stefani MMA; Penna MLF
    Braz J Infect Dis; 2024; 28(2):103745. PubMed ID: 38697216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse reactions induced by MDT/WHO (Rifampicin+Clofazimine+Dapsone) and ROM (Rifampicin+Ofloxacin+Minocycline) regimens used in the treatment of leprosy: a cohort study in a National Reference Center in Brazil.
    Celestino IC; Antunes DE; Santos DF; Gimenes VL; de Souza FM; Goulart IMB
    Front Pharmacol; 2024; 15():1346169. PubMed ID: 38515839
    [No Abstract]   [Full Text] [Related]  

  • 4. Acceptability of clofazimine capsules in children and adolescents with rifampicin-resistant TB.
    Wademan DT; Saule Z; Marthinus A; Viljoen L; Nortier E; Hughes J; Courtney I; Palmer M; Garcia-Prats AJ; Hesseling AC; Hoddinott G
    Int J Tuberc Lung Dis; 2024 May; 28(5):256-258. PubMed ID: 38659140
    [No Abstract]   [Full Text] [Related]  

  • 5. Results of a modified WHO regimen in highly bacilliferous BL/LL patients.
    Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa ; Sharma VD; Shivannavar CT; Katoch VM
    Int J Lepr Other Mycobact Dis; 1989 Jun; 57(2):451-7. PubMed ID: 2664042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT.
    Katoch K; Natarajan M; Bagga A; Katoch VM
    Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):248-54. PubMed ID: 2071982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
    Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
    Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy.
    Katoch K; Katoch VM; Natrajan M; Sreevatsa ; Gupta UD; Sharma VD; Shivanavar CT
    Vaccine; 2004 Sep; 22(27-28):3649-57. PubMed ID: 15315844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy.
    Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa
    Indian J Lepr; 1987; 59(1):36-43. PubMed ID: 3611859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immuno-allergic accidents with rifamipcin].
    Flageul B; Wagner L; Cottenot F
    Acta Leprol; 2001-2002; 12(2):71-8. PubMed ID: 12136739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leprosy. Recognition and treatment.
    Ramos-e-Silva M; Rebello PF
    Am J Clin Dermatol; 2001; 2(4):203-11. PubMed ID: 11705247
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.